JP2003506389A5 - - Google Patents

Download PDF

Info

Publication number
JP2003506389A5
JP2003506389A5 JP2001514908A JP2001514908A JP2003506389A5 JP 2003506389 A5 JP2003506389 A5 JP 2003506389A5 JP 2001514908 A JP2001514908 A JP 2001514908A JP 2001514908 A JP2001514908 A JP 2001514908A JP 2003506389 A5 JP2003506389 A5 JP 2003506389A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutical composition
compound
embedded image
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001514908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003506389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/021503 external-priority patent/WO2001010383A2/en
Publication of JP2003506389A publication Critical patent/JP2003506389A/ja
Publication of JP2003506389A5 publication Critical patent/JP2003506389A5/ja
Pending legal-status Critical Current

Links

JP2001514908A 1999-08-06 2000-08-04 カスパーゼ阻害剤およびその使用 Pending JP2003506389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14770699P 1999-08-06 1999-08-06
US60/147,706 1999-08-06
PCT/US2000/021503 WO2001010383A2 (en) 1999-08-06 2000-08-04 Caspase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2003506389A JP2003506389A (ja) 2003-02-18
JP2003506389A5 true JP2003506389A5 (cg-RX-API-DMAC7.html) 2011-06-30

Family

ID=22522602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001514908A Pending JP2003506389A (ja) 1999-08-06 2000-08-04 カスパーゼ阻害剤およびその使用

Country Status (11)

Country Link
US (1) US6632962B2 (cg-RX-API-DMAC7.html)
EP (1) EP1163208B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003506389A (cg-RX-API-DMAC7.html)
AT (1) ATE266623T1 (cg-RX-API-DMAC7.html)
AU (1) AU6894800A (cg-RX-API-DMAC7.html)
DE (1) DE60010675T2 (cg-RX-API-DMAC7.html)
DK (1) DK1163208T3 (cg-RX-API-DMAC7.html)
ES (1) ES2219381T3 (cg-RX-API-DMAC7.html)
PT (1) PT1163208E (cg-RX-API-DMAC7.html)
TW (1) TWI281910B (cg-RX-API-DMAC7.html)
WO (1) WO2001010383A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165490B1 (en) 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
CA2369619A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AT413485B (de) * 2001-04-09 2006-03-15 Hemoteq Gmbh Mit einem pharmazeutikum beschichteter stent
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
EP1485107A1 (en) 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
EP1499898A2 (en) * 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
GB2389580A (en) * 2002-06-12 2003-12-17 Bayer Ag 2-Naphthamide PGI2 antagonists
JPWO2004073742A1 (ja) * 2003-02-24 2006-06-01 第一製薬株式会社 B型肝炎ウイルスx相互作用蛋白質の分解阻害剤
US7504382B2 (en) * 2003-05-06 2009-03-17 Cytovia, Inc. Protease inhibitors for coronaviruses and SARS-CoV and the use thereof
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
IL158599A0 (en) * 2003-10-26 2004-05-12 Yeda Res & Dev Methods of modulating hematopoiesis
EP1723124A1 (en) * 2004-02-18 2006-11-22 Georgia Tech Research Corporation Propenoyl hydrazides
AU2005223767B2 (en) * 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PL217743B1 (pl) * 2004-05-15 2014-08-29 Vertex Pharma Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
FR2878522B1 (fr) * 2004-12-01 2008-04-18 Merck Sante Soc Par Actions Si Nouveaux inhibiteurs specifiques de la caspas-10
KR20080038369A (ko) * 2005-07-28 2008-05-06 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 프로드럭
US8828950B2 (en) * 2007-05-01 2014-09-09 Cedars-Sinai Medical Center Caspase inhibitors in the treatment of infection-associated preterm delivery
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティBrandeis University Ice阻害化合物およびその使用
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
EA201590916A1 (ru) 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
MX2019003889A (es) 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
CN113354708B (zh) 2017-01-23 2024-05-14 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
WO2022187440A1 (en) 2021-03-03 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services La protien as a novel regulator of osteoclastogenesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618223A3 (en) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
JP2000501428A (ja) * 1996-09-12 2000-02-08 アイドゥン ファーマシューティカルズ,インコーポレイテッド 酵素のice/ced−3プロテアーゼファミリーを阻害する新規な三環式化合物
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
EP1165490B1 (en) * 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
NZ516918A (en) * 2000-05-23 2004-06-25 Vertex Pharma Caspase inhibitors and uses thereof
DE60131160T2 (de) * 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen

Similar Documents

Publication Publication Date Title
JP2003535865A5 (cg-RX-API-DMAC7.html)
JP2003534325A5 (cg-RX-API-DMAC7.html)
JP2014506907A5 (cg-RX-API-DMAC7.html)
JP2004509120A5 (cg-RX-API-DMAC7.html)
JP2006513220A5 (cg-RX-API-DMAC7.html)
CA2440218A1 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands
CA2393710A1 (en) Caspase inhibitors and uses thereof
JP2005504811A5 (ja) 置換ペンタセン化合物、半導体デバイス及び物品
JP2002502874A5 (cg-RX-API-DMAC7.html)
PL367215A1 (en) Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
WO2005037781A3 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
KR970015579A (ko) 테트라졸 화합물
JP2009519993A5 (cg-RX-API-DMAC7.html)
CA2634811A1 (en) Novel modifications to 2-amino-4-(4-fluorobenzylamino) -1- ethoxycarbonyl-aminobenzene and processes for preparing said compound
CA2288789A1 (en) Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands
NO20053211L (no) Forbindelser for behandling av metabolske forstyrrelser.
CA2147883A1 (en) Cyclohexanol Derivative, Cool Feeling and Cool Feeling Composition Containing the Same, Process for Producing the Derivative and Intermediate Therefor
WO2002016355A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
DE60220255T2 (de) N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
JP2019513745A5 (cg-RX-API-DMAC7.html)
CA2526991A1 (en) Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor
JP2009520695A5 (cg-RX-API-DMAC7.html)
JP2010535706A5 (cg-RX-API-DMAC7.html)
JP2007525503A5 (cg-RX-API-DMAC7.html)
CA2467973A1 (en) Pyridine derivatives as nmda receptor ligands